Abstract
In order to simplify and cutting down expenses of the bone marrow transplantation procedures we have made some efforts, trying to provide the best transplantation technique for the individual patient with scarce resources. In relation with the source of stem cells, we have found very attractive the use of peripheral blood stem cells (PBSC) instead of bone marrow cells. This procedure can produce substantially more rapid engraftment than observed with bone marrow. The rapid hematopoietic reconstitution in the recipient of PBSC lower expenses stemming from the use of antibiotics, blood bank products and days at the hospital. In Mxico, a country with a large number of cases of severe aplastic anemia we decided to use PBSC to transplant 10 patients with this disease, in order to take advantage of the large number of stem cells that this procedure can provide. We had excellent results in these patients, avoiding the high cost of the conventional transplantation and the use of ATG. In relation to autologous transplantation we have made efforts to perform autografts without the use of freezing devices, keeping the stem cells in liquid form using a conventional blood bank refrigerator for up to 96 hr. This modifications have resulted in diminishing costs and increasing the availability of the procedure to a large number of patients. Finally in Mxico we have had experience with non-myeloablative transplants, and obtained reasonably good results, with a median cost of 18,000 USD per allogeneic transplantation procedure. In some cases this is the only affordable therapeutic option. In developing countries where very few patients can afford the cost of conventional bone marrow transplants, any reasonable effort in the direction of simplification must be welcome.
Similar content being viewed by others
References
Korbling M, Fliedner TM Historical perspective the evolution of clinical peripheral blood stem cell transplantation.Bone Marrow Transpl. 1996;17:675–678.
Besinger WI, Clift T, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies.Blood. 1996;88:2794–2800.
Delgado-Lamas JL, López-Karpovitch X, Marn-López A, et al. Low doses of high potency antithymocyte globulin (ATG) in severe aplastic anemia: Experience with the Mexican ATG.Acta Hematol. 1989;81:70–74.
Storb R, Weiden PL, Sullivan KM, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patiets with aplastic anemia.Blood. 1994;84:941–949.
Herrera-Garza JL, Jaime-Pérez JC, Gómez-Almaguer D, et al. High dose peripheral blood stem cell transplant for multitransfused severe aplastic anemia patients without antithymocyte globulin in the conditioning regimen.Bone Marrow Transpl. 1999;24:845–848.
Martin PJ, Akatuska Y, Hahne M, Sale G. Involvement of donor T-cell cytotoxic elector mechanisms in preventing allogeneic marrow graft refection.Blood. 1998;92:2177–2181.
Gratwohl A, Schmitz N. First International Symposium on allogeneic peripheral blood precursor cell transplants.Bone Marrow Transpl. 1996;17:S1-S3.
Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, et al. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high dose chemotherapy.Am J Hematol. 1995;48:100–103.
Ossenkipele GJ, Jpnjhoff AR, Huigens PCV, et al. Reinfusion of unprocessed whole blood after G-CSF induced stem cell mobilization shortens the pancytopenic period after high dose melphalan.Blood. 1993;82 (Suppl):264a.
Feremans WW, Bastin G, Le Moine F, et al. Simplification of the blood stem cell transplantation procedure: Large volume apheresis and uncontrolled rate cryopreservation at 80C.Eur J Haematol. 1996;55:278–282.
Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, et al. Non cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis.Am J Hematol. 1998;58:161–164.
Slavin S, Nagler A, Naparstak E, et al. Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematological diseades.Blood. 1998;91:756–763.
Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harmessing graft-versus-leukemia without myeloablative chemotherapy.Blood. 1997;89:4531–4536.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis.Bone Marrow Transpl. 2000;25:131–133.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, et al. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens.Am J Hematol. 2001;66:241–244.
Author information
Authors and Affiliations
About this article
Cite this article
Gómez-Almaguer, D. The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 76 (Suppl 1), 380–382 (2002). https://doi.org/10.1007/BF03165288
Issue Date:
DOI: https://doi.org/10.1007/BF03165288